FOLFIRINOX/mFOLFIRINOX
Phase 1Small molecule
Innovent Biologics (Suzhou) Co. Ltd.FOLFIRINOX/mFOLFIRINOX is one of 7 small molecule programs targeting Locally Advanced Unresectable or Metastatic Solid Tumors. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Locally Advanced Unresectable or Metastatic Solid Tumors
#DrugCompanyPhaseTrials
1Tuoyi
CCoherus Oncology, Inc.
Phase 2
RC148
RRemeGen Co., Ltd.
Phase 2
IBI343
Innovent Biologics (Suzhou) Co. Ltd.Phase 1
IBI354
Innovent Biologics (Suzhou) Co. Ltd.Phase 2
RC118
RRemeGen Co., Ltd.
Phase 2
Mfolfox
Arcus BiosciencesPhase 1
FOLFIRINOX/mFOLFIRINOX
Innovent Biologics (Suzhou) Co. Ltd.Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FOLFIRINOX/mFOLFIRINOX. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details